Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

COSTEM 2019 | Should maintenance therapy after autograft be limited?

Philip McCarthy • 26 Oct 2019
COSTEM 2019
Multiple Myeloma Lenalidomide
Myeloma XI

Philip McCarthy, MD, Roswell Park Comprehensive Cancer Center, Buffalo, NY, talks on limiting maintenance therapy after autograft. This interview took place at the 5th International Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM) 2019, held in Berlin, Germany.

More from Philip McCarthy

Treatment-free intervals: what is best for patients?
4:02
Treatment-free intervals: what is best for patients?
Philip McCarthy • 1 Sep 2021
Future maintenance therapy approaches for multiple myeloma
4:22
Future maintenance therapy approaches for multiple myeloma
Philip McCarthy • 1 Sep 2021
CAR-T for myeloma: where are we now and where are we going?
5:15
CAR-T for myeloma: where are we now and where are we going?
Philip McCarthy • 1 Sep 2021
Does maintenance therapy increase overall survival in myeloma?
10:09
Does maintenance therapy increase overall survival in myeloma?
Philip McCarthy • 13 Sep 2019

Related Videos

Updated results from the iMMagine-1 trial of anito-cel in R/R multiple myeloma
4:32
Updated results from the iMMagine-1 trial of anito-cel in R/R multiple myeloma
Philip McCarthy • 18 Dec 2025
Investigating AZD0120, a dual-targeting CAR-T product, in R/R myeloma: DURGA-1 preliminary results
3:36
Investigating AZD0120, a dual-targeting CAR-T product, in R/R myeloma: DURGA-1 preliminary results
Philip McCarthy • 7 Dec 2025
A Phase II trial investigating IberKDd in R/R multiple myeloma: the ReKInDLE study
3:11
A Phase II trial investigating IberKDd in R/R multiple myeloma: the ReKInDLE study
Philip McCarthy • 7 Dec 2025
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
4:04
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
Philip McCarthy • 15 Dec 2025
The content of VJHemOnc is intended for healthcare professionals